Our Mission
Advancing the understanding and treatment of Substance Use Disorder through neuroscience and personalized medicine.
The Clinical Problem
Treatment Gap in Addiction Care
Substance Use Disorder (SUD) affects millions of individuals and families. Traditional assessments rely heavily on subjective self-reports, which may not fully capture the neurobiological factors underlying addiction, craving, and relapse risk.
Need for Objective Measures
Clinical decision-making in addiction treatment has historically lacked objective, brain-based biomarkers. Research indicates that neural responses to drug-related cues can predict relapse risk, yet these measures have not been widely integrated into clinical practice.
Scientific Approach
Our approach is grounded in peer-reviewed neuroscience research demonstrating that specific brain activity patterns correlate with craving and relapse vulnerability. Founded by Scott Burwell, PhD, Neurotype Inc. translates laboratory findings into tools that may complement clinical assessment and treatment planning.
Research Foundation
Our work is supported by Small Business Innovation Research (SBIR) awards from the National Institute on Drug Abuse (NIDA). We are developing and testing a brain-based biomarker platform through clinical trials, with patented technology aimed at bridging the gap between neuroscience research and clinical application.
What We Are Building
NeuromarkR™ is an investigational EEG-based assessment / clinical decision support tool under development, intended to provide clinicians with objective data on neural responses to substance-related cues. Modit™ is an experimental closed-loop neurofeedback intervention being studied for its potential to modulate brain responses to environmental triggers.
